Half Yearly Report and Accounts

• Revenue increased by 6.1% to $48.3 million for the half-year ended 30 June 2026
• Profit before income tax rose by 19.1% to $8.1 million
• Net profit after tax increased by 14.9% to $5.5 million
• Dividend per share increased by 0.5 cents to 5.0 cents

Vita Life Sciences Ltd reported a strong first half performance for the six months ended 30 June 2026, with revenue increasing by 6.1% to $48.3 million and profit before income tax rising by 19.1% to $8.1 million compared to the previous corresponding period (PCP). Profit growth exceeded revenue growth, reflecting improved operating margins, a favorable product mix, and ongoing cost discipline. Key highlights include revenue growth in Australia and Malaysia/Singapore, improved gross profit margin driven by an improved product mix, and continued investment in brand-building initiatives. The Group maintains a strong balance sheet with total equity of $55.7 million and cash reserves of $33.7 million as of 30 June 2026. The Directors declared a partially franked interim dividend of 5.0 cents per share, an increase of 0.5 cents per share compared with the PCP. The dividend will be franked at 60%. The unfranked portion of the dividend was sourced from the Company's conduit foreign income account.

Revenue: $48.3 million, Profit before tax: $8.1 million, Net profit after tax: $5.5 million

The Board will closely monitor ongoing market and consumer sentiment and will provide further outlook in the fourth quarter.